[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-disease-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-disease-risk":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100520857","potassium-hydration-cardiovascular-and-kidney-study-phacks-100520857",false,"NCT06062017","Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)","The Effects of Water and Potassium Supplementation on Cardiovascular and Kidney Function in Young Adults","PHACKs","Inclusion Criteria:\n\n* Between the ages of 18-30 years\n* Resting blood pressure no higher than 150\u002F90 mmHg\n* BMI below 35 kg\u002Fm2\n* Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer.\n\nExclusion Criteria:\n\n* Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood.\n* Are currently pregnant or trying to become pregnant.\n* take any of the following medications that are contraindicated with potassium supplementation:\n* Renin-angiotensin-aldosterone system (RAAS) blockers: Candesartan , Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan\n* Non -steroidal anti-inflammatory medications: Aspirin, Ibuprofen, Naproxen\n* Non-selective beta-blockers: Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol\n* Calcineurin inhibitors: Cyclosporine\n* Heparin (or other blood thinning medications)",true,"ALL","18 Years","30 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States. Inadequate hydration status is associated with risk factors for both CVD and CKD. Prior data show that Black individuals are less likely to be adequately hydrated when compared with their White counterparts. Further, socioeconomic factors have been shown to influence hydration practices. Inadequate hydration influences certain hormones that regulate blood volume and impact blood pressure, but increasing potassium intake may provide some positive effects on normalizing these hormones and blood pressure. Black adults, in particular, are more likely to consume less potassium, have inadequate hydration, and tend to have higher blood pressure. As such, there is a critical need for effective strategies to address racial disparities in hydration and resultant health consequences; as well as establish the role of socioeconomic factors contributing to hydration. Therefore, the investigators are seeking to test the investigators' central hypothesis that water with a potassium supplement will improve hydration and cardiovascular health in young White adults (n = 20, 10 females, 10 males), and to a greater extent in young Black Adults (n = 20, 10 females, 10 males. The investigators will assess measures of blood pressure, arterial stiffness, and biomarkers in the urine and blood samples prior to and following a 14-day hydration intervention of 1) bottled water and 2) bottled water with potassium supplementation (2000mg potassium\u002Fday).",[29,30,31],"Blood Pressure","Hydration","Vascular Disease Risk",[33,30,34,35,36],"Racial disparities","Blood pressure","Vascular function","Potassium","RECRUITING","2025-02-25",{"date":40,"type":41},"2025-02-27","ACTUAL",{"date":43,"type":41},"2024-11-06",{"date":45,"type":23},"2027-07",{"name":47,"class":48},"Auburn University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100580816","interactive-roles-of-cardiorespiratory-fitness-and-adiposity-on-glucose-and-vascular-control-after-physical-inactivity-100580816","NCT06842225","Interactive Roles of Cardiorespiratory Fitness and Adiposity on Glucose and Vascular Control After Physical Inactivity","Interactive Roles of Cardiorespiratory Fitness and Adiposity on Recovery of Impaired Glucose and Vascular Control After Physical Inactivity","Inclusion Criteria:\n\n* Males and females 18 to 40 years of age.\n* Ability to safely ride an electric scooter (e-scooter) for at least 10 minutes.\n* Active (\\>7000 steps per day, walking \\> 1 mile a day outside)\n* Stable body weight for at least 1 year\n* aerobic fitness level, CRF is \\\u003C 9 and \\>14 METS\n* Visceral adipose tissue \\\u003C130 cm2 or ≥130 cm2 for men and \\\u003C100 cm2 or ≥100 cm for women\n\nExclusion Criteria:\n\n* Any injury preventing them from exercising regularly at the time of the screening.\n* Implantable defibrillator or pacemaker\n* Active cancer\n* Alcohol or drug abuse\n* Use of an assistive walking device\n* Presence of significant signs\u002Fsymptoms of cardiovascular, metabolic, or pulmonary disease (determined from the American College of Sports Medicine (ACSM) Health History Questionnaire)\n* Daily vitamin consumption of \\> 500mg per day during the study\n* Acetaminophen or aspirin use during the study","40 Years",{"count":59,"type":23},48,[26],"The far-reaching negative health effects of the reduced physical activity (RPA) epidemic are often overlooked by the general population and health professionals. Short-term RPA induces cardiometabolic dysfunction, including impaired glucose control and vascular function, that may precede disease development. The impact of existing health status on RPA-induced cardiometabolic dysfunction and recovery of impaired glucose control following RPA is unexplored. Thus, the investigators' objectives are 1) to investigate the effect of existing health status (cardiorespiratory fitness and adiposity) on the recovery of impaired glucose control following a period of RPA and 2) to determine the role of vascular function as a mechanism of impaired glucose control. The investigators' final objective is to 3) expose undergraduate students to meritorious biomedical clinical research methods. The investigators have piloted the clinical research methods and analysis with undergraduate researcher associates and are well-prepared to complete this proposal. Preliminary data show that low cardiorespiratory fitness and\u002For high adiposity impair the recovery of glucose control following short-term RPA. Thus, the investigators aim to examine the interactive role of health status (cardiorespiratory fitness and adiposity) on the ability to recover impaired glucose control following short-term RPA. The investigators also seek to examine changes in vascular function as a mechanism of recovery of impaired glucose control following a return to normal PA. The investigators will recruit men and women with divergent health status (cardiorespiratory fitness and adiposity) to examine glucose control and vascular function during 7-d of normal PA, 7-d of RPA, and 7-d of resumption of normal RA. Continuous glucose monitoring and oral glucose tolerance tests will be performed to assess glucose control. Increases in vascular shear stress induced by passive leg movement and central arterial stiffness will be measured to assess vascular function.",[63,64,31],"Metabolic Disorders","Physical Inactivity",[66,67,68],"physical activity","glucose control","vascular function","NOT_YET_RECRUITING","2025-02-18",{"date":72,"type":41},"2025-02-24",{"date":74,"type":23},"2025-06-01",{"date":76,"type":23},"2029-06-30",{"name":78,"class":48},"Miami University"]